Multiple Myeloma

The Multiple Myeloma pipeline: 154 tracked drugs, 22 approved for this indication.

22 approved / phase 428 Phase 38 Phase 233 Phase 1/247 Phase 11 US approval withdrawn15 preclinical / unstaged

Compare the share prices of listed companies in Multiple Myeloma →

Total attributable cost

$11.1B

$54,968/patient

Drug spend

Not yet sourced

How this is calculated ↗

All stages, prevalent population (2023 SEER estimate) · US

The Multiple Myeloma pipeline

Key trial results for every approved and late-stage drug: Multiple Myeloma results by drug.

← all assets